United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
